Endometrial cancer is the second most common gynecologic cancer worldwide, and researchers continue to search for ways to reduce the risk of recurrence after initial treatment. While significant progress has been made in advanced disease, preventing cancer from returning remains a major challenge.
A new phase 3 clinical trial known as DESTINY-Endometrial02 is evaluating whether ENHERTU (trastuzumab deruxtecan) can help patients with HER2-expressing endometrial cancer when used earlier in treatment. The study reflects growing interest in bringing targeted therapies into earlier stages of care, where they may have the greatest impact.
Understanding HER2 in Endometrial Cancer
HER2 is a protein found on the surface of some cancer cells.
When too much HER2 is present, tumors may:
- Grow more quickly
- Become more aggressive
- Be more likely to recur
HER2 is well known in breast cancer, but researchers have also identified HER2 overexpression in certain endometrial cancers, particularly aggressive subtypes.
Testing for HER2 helps identify patients who may benefit from HER2-targeted therapies.
What Is ENHERTU?
ENHERTU is a type of treatment known as an antibody-drug conjugate.
It combines:
- A HER2-targeting antibody
- A powerful chemotherapy payload
The antibody acts like a delivery system, guiding chemotherapy directly to HER2-expressing cancer cells while limiting exposure to healthy tissues.
This targeted approach has already shown promising results in several HER2-positive cancers.
What is an Antibody Drug Conjugate?
An antibody-drug conjugate (ADC) is a medicine that uses a targeted antibody to deliver a powerful cancer-killing drug directly to tumor cells. It’s designed to reduce damage to healthy cells by concentrating the toxic drug where it’s needed most
Why This Trial Is So Important
Most studies involving ENHERTU have focused on patients with advanced or metastatic disease.
The DESTINY-Endometrial02 trial is different because it evaluates the drug as adjuvant therapy, meaning treatment given after surgery and other primary therapies to reduce the risk of recurrence.
Researchers hope that using targeted therapy earlier may help eliminate microscopic cancer cells before they can cause the disease to return.
A New Era of Personalized Treatment
The trial reflects a broader shift toward precision medicine in gynecologic oncology.
Rather than treating all endometrial cancers the same way, doctors are increasingly using molecular testing to identify patients who may benefit from specific therapies.
HER2 testing is becoming an important part of this process, helping match patients with treatments designed to target the biology of their tumor.
Looking Ahead
The DESTINY-Endometrial02 study is still ongoing, and researchers will need time to determine whether ENHERTU improves outcomes in patients with HER2-expressing endometrial cancer.
However, the launch of this phase 3 trial highlights the growing momentum behind targeted therapies and personalized treatment approaches. If successful, the study could help establish a new standard of care for a subset of endometrial cancer patients and further expand the role of precision medicine in gynecologic oncology.
Source
Daiichi Sankyo. DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer. 2025. Accessed by: https://daiichisankyo.us/press-releases/-/article/destiny-endometrial02-phase-3-trial-of-enhertu-initiated-as-adjuvant-therapy-in-patients-with-her2-expressing-endometrial-cancer
